BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38643353)

  • 1. p53 immunohistochemistry as an ancillary tool for rapid assessment of residual disease in TP53-mutated acute myeloid leukemia and myelodysplastic syndromes.
    Brar N; Lawrence L; Fung E; Zehnder JL; Greenberg PL; Mannis GN; Zhang TY; Gratzinger D; Oak J; Silva O; Kurzer J; Tan B; Menke JR; Fernandez-Pol S
    Am J Clin Pathol; 2024 Apr; ():. PubMed ID: 38643353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1.
    Zhou Y; Moon A; Hoyle E; Fromm JR; Chen X; Soma L; Salipante SJ; Wood BL; Wu D
    Cytometry B Clin Cytom; 2019 Jan; 96(1):67-72. PubMed ID: 30417521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemistry screening for TP53 mutation in myeloid neoplasms in AZF-fixed bone marrow biopsies.
    Yang G; Anderson Williams S; He F; He Y; McIntyre K; Beckman AK; Nelson AC; Yohe SL
    Pathology; 2024 Apr; 56(3):404-412. PubMed ID: 38341302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiplex imaging reveals spatially resolved DNA-damage response neighborhoods in TP53-mutated myelodysplastic neoplasms.
    Yeung T; Zhang Y; Kennedy B; Walsh C; Love T; Xia D; Bhattacharya A; Krishnan RG; Head D; Burack R
    J Pathol; 2024 Jul; 263(3):386-395. PubMed ID: 38801208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next-generation sequencing-based minimal residual disease monitoring in patients receiving allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia or myelodysplastic syndrome.
    Shapiro RM; Kim DDH
    Curr Opin Hematol; 2018 Nov; 25(6):425-432. PubMed ID: 30281033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of immunohistochemical markers in bone marrow sections to evaluate for myelodysplastic syndromes and acute myeloid leukemias.
    Dunphy CH; O'Malley DP; Perkins SL; Chang CC
    Appl Immunohistochem Mol Morphol; 2007 Jun; 15(2):154-9. PubMed ID: 17525626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of p53 immunohistochemistry with TP53 mutational status and overall survival in newly diagnosed acute myeloid leukaemia.
    Fitzpatrick MJ; Boiocchi L; Fathi AT; Brunner AM; Hasserjian RP; Nardi V
    Histopathology; 2022 Oct; 81(4):496-510. PubMed ID: 35869818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deep Molecular and In Silico Protein Analysis of p53 Alteration in Myelodysplastic Neoplasia and Acute Myeloid Leukemia.
    Madarász K; Mótyán JA; Bedekovics J; Miltényi Z; Ujfalusi A; Méhes G; Mokánszki A
    Cells; 2022 Nov; 11(21):. PubMed ID: 36359870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse.
    Press RD; Eickelberg G; Froman A; Yang F; Stentz A; Flatley EM; Fan G; Lim JY; Meyers G; Maziarz RT; Cook RJ
    Am J Hematol; 2019 Aug; 94(8):902-912. PubMed ID: 31124175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
    Orazi A
    Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in
    Patkar N; Kodgule R; Kakirde C; Raval G; Bhanshe P; Joshi S; Chaudhary S; Badrinath Y; Ghoghale S; Kadechkar S; Khizer SH; Kannan S; Shetty D; Gokarn A; Punatkar S; Jain H; Bagal B; Menon H; Sengar M; Khattry N; Tembhare P; Subramanian P; Gujral S
    Oncotarget; 2018 Nov; 9(93):36613-36624. PubMed ID: 30564301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Multiple Clinical Testing Modalities for Assessment of NPM1-Mutant AML.
    Lopez A; Patel S; Geyer JT; Racchumi J; Chadburn A; Simonson P; Ouseph MM; Inghirami G; Mencia-Trinchant N; Guzman ML; Gomez-Arteaga A; Lee S; Desai P; Ritchie EK; Roboz GJ; Tam W; Kluk MJ
    Front Oncol; 2021; 11():701318. PubMed ID: 34527579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes.
    Duncavage EJ; Tandon B
    Int J Lab Hematol; 2015 May; 37 Suppl 1():115-21. PubMed ID: 25976969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical detection of p53, mdm2, waf1/p21, and Ki67 proteins in bone marrow biopsies in myelodysplastic syndroms, acute myelogenous leukaemias and chronic myeloproliferative disorders.
    Kanavaros P; Stefanaki K; Rontogianni D; Darivianaki K; Vlychou M; Papadaki E; Eliopoulos G; Bakiri M; Matsouka C; Kakolyris S; Georgoulias V
    Clin Exp Pathol; 1999; 47(5):231-8. PubMed ID: 10598372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome.
    Grob T; Al Hinai ASA; Sanders MA; Kavelaars FG; Rijken M; Gradowska PL; Biemond BJ; Breems DA; Maertens J; van Marwijk Kooy M; Pabst T; de Weerdt O; Ossenkoppele GJ; van de Loosdrecht AA; Huls GA; Cornelissen JJ; Beverloo HB; Löwenberg B; Jongen-Lavrencic M; Valk PJM
    Blood; 2022 Apr; 139(15):2347-2354. PubMed ID: 35108372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blast counts are lower in the aspirate as compared to trephine biopsy in acute myeloid leukemia and myelodysplastic syndrome expressing CD56.
    Drexler B; Tzankov A; Martinez M; Baerlocher S; Passweg JR; Dirnhofer S; Tsakiris DA; Dirks J
    Int J Lab Hematol; 2021 Oct; 43(5):1078-1084. PubMed ID: 33709561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.
    Cloos J; Harris JR; Janssen JJWM; Kelder A; Huang F; Sijm G; Vonk M; Snel AN; Scheick JR; Scholten WJ; Carbaat-Ham J; Veldhuizen D; Hanekamp D; Oussoren-Brockhoff YJM; Kaspers GJL; Schuurhuis GJ; Sasser AK; Ossenkoppele G
    J Vis Exp; 2018 Mar; (133):. PubMed ID: 29553571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-level MYC expression associates with poor survival in patients with acute myeloid leukemia and collaborates with overexpressed p53 in leukemic transformation in patients with myelodysplastic syndrome.
    Gao L; Saeed A; Golem S; Zhang D; Woodroof J; McGuirk J; Ganguly S; Abhyankar S; Lin TL; Cui W
    Int J Lab Hematol; 2021 Feb; 43(1):99-109. PubMed ID: 32812335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and Classification of Myelodysplastic Syndromes with Mutated TP53.
    Siddon AJ; Weinberg OK
    Clin Lab Med; 2023 Dec; 43(4):607-614. PubMed ID: 37865506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
    Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
    Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.